This website uses cookies in order to improve our services. If you proceed visiting this website you accept the usage of cookies. For more info please read our Data Privacy statement.

 

Hematologic Cancer NGS Panels


General Cancer Testing | Brain & CNS Cancer | Breast & Ovarian Cancer | Colorectal & Prostate Cancer | Endocrine & Thyroid Cancer | Gastric Cancer | Hematologic Cancer | Kidney Cancer | Lung Cancer | Pancreatic Cancer | Skin Cancer & Melanoma | Solid Tumors | Less Common Cancers


Haematological malignancies also known as blood cancer is a subgroup of the haematopoietic and lymphoid malignancies. Types of haematological malignancies include leukemias (Acute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic lymphocytic leukemia (CLL)), lymphomas (Chronic myelogenous leukemia (CML), Acute monocytic leukemia (AMoL)) and myelomas. 

On this page NGS panels are listed that target genes that are related or supposed to be related to the development of hematologic cancers. Some NGS panels are specific for leukemia, lymphoma or myeloma, some target genes that are associated with all three cancer types. Therefore, the number of targeted genes vary from a few to over 100 genes depending on the panel.

For more information on the targeted genes please contact the NGS panel provider, general information on the different types of hematologic cancers are found on this website.


Hematologic Cancer (including Leukemia, Lymphoma and Myeloma)

FoundationOne Heme

FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is Foundation Medicine's second commercially available targeted sequencing assay.
source FoundationOne

Website

Hematopoietic Disorders Gene Set

Targeted genes: ABL1, ASXL1, ATM, BCOR, BIRC3, BRAF, CALR, CBL, CEBPA, CREBBP, CSF1R, CSF3R, DNMT3A, EP300, ETV6, EZH2, FBXW7, FGFR4, FLT3, GATA1, GATA2, GATA3, IDH1, IDH2, IL7R, JAK2, JAK3, KDM6A, KIT, KRAS, KMT2A*, MPL, NF1, NOTCH1, NOTCH2, NPM1, NRAS, NSD1, PAX5, PDGFRA, PDGFRB, PTPN11, RUNX1, SETB1, SF3B1, SRSF2, STAG2, TERT, TET1, TET2, TP53, TSLP, U2AF1 and ZRSR2 (*rearrangements also detected)
Source: WUSTL

Hereditary Lymphoma Panel

Our Tier 1: Hereditary Lymphoma Panel includes sequencing and deletion/duplication analysis of the following 8 genes: CHEK2, KLHDC8B, NPAT, TP53, MLH1, MSH2, MSH6 and PMS2.

Source: The University of Chicago Genetic Services

MyAML™ panel

Our MyAML™ panel screens for nearly 200 genes that may be associated with the development of AML, including 36 important fusions. With reports geared to help identify pertinent therapies and relevant clinical trials, we at Genection are helping doctors and their patients either newly diagnosed with AML, or those patients out of remission.
Source: genection

Website


Leukemia

AML / MDS NEXT GEN SEQUENCING LEUKEMIA PANEL

Screening for mutations in oncogenes and tumor suppressor genes is increasingly important in delivering personalized cancer care. The AML/MDS Genotyping Panel delivers information on predictive and prognostic mutations commonly involved in acute myelogenous leukemia and myelodysplasias, as well as detecting some mutations that may directly inform targeted or non-targeted treatment options. The panel has a sensitivity of ~5 % mutant allele with strict next generation sequencing quality control parameters.
Source: Responsegenetics

Website

CLL MASTR Plus

For identification of somatic mutations in 9 genes associated with Chronic Lymphocytic Leukemia (CLL) The CLL MASTR Plus is a molecular assay for the identification of both SNVs and CNAs in 9 selected genes (listed under the specifications tab) in individuals with indication of CLL. Multiplicom’s CLL MASTR Plus assay is provided as a ready-to-use kit that offers robust performance with minimum hands-on time. All reagents for multiplex amplification of 251 unique amplicons (261-437 bp), ensuring complete coverage of all coding sequences in 6 PCR reactions are included.
Source: multiplicom

Website

ClearSeq AML

The ClearSeq AML targets 20 genes found to be frequently mutated in acute myeloid leukemia (AML).This panel is designed for full coverage of target regions with multiple amplicons covering each target for greater confidence in somatic variant calling.
Compatible with HaloPlex Target Enrichment System.
Source: Agilent

Website

Familial Myelodysplastic Syndrome/Acute Leukemia Panel

Our Tier 1: Familial Myelodysplastic Syndrome/Acute Leukemia Panel includes sequence and deletion/duplication analysis of the following 10 genes: ANKRD26, CEBPA, GATA2, RUNX1, SRP72, TERC, TERT, TP53, plus sequence analysis only of ETV6 and DDX41.

Source: The University of Chicago Genetic Services

GS GType TET2/CBL/KRAS

Obtain a comprehensive picture of genetic variation for four key human genes using the GS GType TET2/CBL/KRAS Primer Set. Accurately identify variants associated with developmental defects, disease progression, and residual disease in a variety of leukemias and myeloid malignancies using next-generation deep sequencing of PCR amplicons. This complete solution includes primer sets, protocols, and dedicated analysis software, such as the 454 GS Amplicon Variant Analyzer software or JSI Medical Systems’ SeqNext Software.
Source: Roche

Website

Invitae Myelodysplastic Syndrome/Leukemia Panel

This test analyzes up to 21 genes that are associated with a hereditary predisposition to the development of myelodysplastic syndrome (MDS) and acute leukemias. These genes were selected based on the available evidence to date to provide Invitae’s most comprehensive hereditary MDS/leukemia panel. Some of these genes are also associated with an increased risk of other cancer types.
In addition to the primary panel, clinicians can also choose to include five genes that have limited evidence of association with MDS/leukemia.
Source: Invitae

xGen® Acute Myeloid Leukemia Cancer Panel

The xGen® AML Cancer Panel v1.0 provides 11,743 individually synthesized and quality controlled xGen Lockdown® Probes to achieve deep enrichment of targets from more than 260 genes associated with the AML disease pathway.

Source: IDT


Myeloid

Focus::Myeloid™

Focus::Myeloid™ is a unique NGS panel with 54 biomarkers that provides actionable information for improved diagnosis, prognosis, and risk stratification. Based on the Focus::Myeloid™ result, each patient can receive the most suitable treatment tailored to their unique cancer. By personalizing diagnosis and improving risk stratification, Focus::Myeloid™ delivers on the promise of precision medicine and is designed for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).
Source: Cancer genetics

Website

Human Myeloid Neoplasms Panel

The Human Myeloid Neoplasms GeneRead DNAseq Targeted Panel is a collection of multiplexed PCR primer assays for targeted enrichment of the coding (exonic) regions of the 50 genes most commonly mutated in human myeloid leukemia samples. Mutations in these oncogenes and tumor suppressor genes are often relevant for cancer classification, and warrant extensive investigation to enhance the understanding of carcinogenesis. The term myeloid leukemia covers a spectrum of diseases called hematological neoplasms, but mostly refers to cancer of the blood or bone marrow characterized by an abnormal increase in immature myeloid white blood cells.
Source: Qiagen

Myelofibrosis NGS panel

Targeted Genes: CALR, JAK2, MPL, SH2B3
Source: Fulgent Diagnostics

Myeloid Malignancies Mutation Panel

Assesses for single gene mutations, including substitutions and insertions and deletions that may have diagnostic, prognostic, and/or therapeutic significance in
•Acute myeloid leukemia
•Myelodysplastic syndromes
•Myeloproliferative neoplasms
•MDS/MPN overlap disorders such as chronic myelomonocytic leukemia
Genes tested: ASXL1, ASXL2, BCOR, BCORL1, BRAF, BRINP3, CALR, CBL, CEBPA, CSF3R, DNMT1, DNMT3A, EED, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, HNRNPK, IDH1, IDH2, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MAP2K1, MPL, NOTCH1, NPM1, NRAS, NSD1, PHF6, PRPF40B, PRPF8, PTPN11, RAD21, RUNX1, SETBP1, SF1, SF3A1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, SUZ12, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2
Source: Arup Laboratories

Myeloid Tumor Panel

Tested genes BL1 (Ex4-Ex6), ASXL1 (Ex12), ATRX (Ex08-10, Ex17-31), BCOR (full gene), BCORL1 (full gene), BRAF (Ex15), CALR (Ex09), CBL (Ex08-E09), CBLB (Ex09, Ex10), CBLC (Ex09, Ex10), CDKN2A (full gene), CEBPA (full gene), CSF3R (Ex14-Ex17), CUX1 (full gene), DNMT3A (full gene), ETV6/TEL (full gene), EZH2 (full gene), FBXW7 (Ex09-Ex11), GATA1 (Ex02), GATA2 (Ex02-Ex06), GNAS (Ex08-Ex09), HRAS (Ex02-Ex03), IDH1 (Ex04), IDH2 (Ex04), IKZF1 (full gene), JAK2 (Ex12, Ex14), JAK3 (Ex13), KDM6A (full gene), KIT (Ex2, Ex08-Ex11, Ex13, Ex17), KRAS (E02-E03), MLL (Ex05-Ex08), MPL (Ex10), MYD88 (Ex03, Ex04, Ex05), NOTCH1 (Ex26-Ex27, Ex34), NPM1 (Ex12), NRAS (Ex02-Ex03), PDGFRA (Ex12, Ex14, Ex18), PHF6 (full gene), PTEN (Ex05, Ex07), PTPN11 (Ex3, Ex13), RAD21 (full gene), RUNX1 (full gene), SETBP1 (Ex04 (partial)), SF3B1 (Ex13-Ex16), SMC1A (Ex2, Ex11, Ex16, Ex17), SMC3 (Ex10, Ex13, Ex19, Ex23, Ex25, Ex28), SRSF2 (Ex01), STAG2 (full gene), TET2 (Ex3-Ex11), TP53 (Ex2-Ex11), U2AF1 (Ex02, Ex06), WT1 (Ex07, Ex09), ZRSR2 (full gene)

Source: Centogene

SureSeq Myeloid Panel

The SureSeq Myeloid Panel is a 25-gene myeloid disorders hybridisation-based NGS enrichment panel with complimentary SureSeq Interpret Software that delivers accurate and easy identification of variants.
Source: Oxford Gene Technology

Website

ThunderBolts™ Myeloid Panel

The ThunderBolts™ Myeloid Panel is a next-generation sequencing (NGS) assay for profiling important mutations in known genes implicated in the causation, prognosis and recurrence of myeloid disorder research. Developed in collaboration with a consortium of hematology oncology experts from comprehensive cancer centers in the U.S. and Europe, the panel runs on the ThunderBolts™ System and features NGS breakthroughs in sequence coverage and uniformity, allelic sensitivity, sample input requirements, and workflow.
Source: Raindance Technologies

Website


Pin It